Jun 2026 (Q2 FY26) — Aug 5, 2026
BeOne Medicines AG Q2 FY26 — Strong BRUKINSA Performance and Pipeline Advancement Drive Raised Guidance
Read the full callBeOne Medicines AG (ONC) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
BeOne Medicines AG earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,705 | +29.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 19.1 | +12.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 237 | +151.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
17 of 19 judged targets kept · 17 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| B7-H4 ADC (BG-C9074) dose-escalation efficacy/safety data disclosure at a major medical congress | first half of 2026 | Dec 2025 | At ASCO, we presented data that supports its potential to become a leading program in ovarian cancer. | Achieved |
| Full-year GAAP operating expenses | $4.7 billion to $4.9 billion | Dec 2025 | a modest increase in operating expenses to an updated range of $4.8 billion to $5 billion. | Revised Down |
| IRAK4 CDAC immunology proof-of-concept readout, rheumatoid arthritis | during 2026 | Dec 2025 | we made a data-driven decision not to pursue IRAK4 in rheumatoid arthritis | Missed |
2 of BeOne Medicines Ltd.'s 36 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 33 more targets are in the full ledger.
Claimed
- Total revenues reached $1.7 billion, representing 30% growth year-over-year.
- BRUKINSA global revenues exceeded $1.2 billion, growing 31% year-over-year, driven by highest new patient starts and strong performance across all 5 approved indications.
- Adjusted income from operations increased to $503 million, up over 80% year-over-year, demonstrating scalability.
- FDA approval of BEQALZI as the first and only BCL2 inhibitor in mantle cell lymphoma.
- Successful Phase III MANGROVE study for BRUKINSA, showing a chemo-free regimen was superior to standard of care with a hazard ratio of 0.57.
Qualified
- The CELESTIAL 301 study did not reach statistical superiority in the uMRD analysis versus the VO regimen, though the IDMC recommended continuation for the PFS endpoint.
- A tax audit settlement had an approximate $60 million impact on net income.
Price
$370.17 +0.30% · +$1.11
Performance +17.0% 1Y
1Y: $316.42 on 17 Oct 2025 → $370.17. High $377.47 (12 Nov 2025), low $260.27 (11 Jun 2026).
- Previous close
- $369.06
- 52-week range
- $260.27 – $377.47
- One year
- +16.19%
Overview
- Symbol
- ONC
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
17 of 19 judged targets kept · 17 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| B7-H4 ADC (BG-C9074) dose-escalation efficacy/safety data disclosure at a major medical congress | first half of 2026 | Dec 2025 | At ASCO, we presented data that supports its potential to become a leading program in ovarian cancer. | Achieved |
| Full-year GAAP operating expenses | $4.7 billion to $4.9 billion | Dec 2025 | a modest increase in operating expenses to an updated range of $4.8 billion to $5 billion. | Revised Down |
| IRAK4 CDAC immunology proof-of-concept readout, rheumatoid arthritis | during 2026 | Dec 2025 | we made a data-driven decision not to pursue IRAK4 in rheumatoid arthritis | Missed |
Claimed
- Total revenues reached $1.7 billion, representing 30% growth year-over-year.
- BRUKINSA global revenues exceeded $1.2 billion, growing 31% year-over-year, driven by highest new patient starts and strong performance across all 5 approved indications.
- Adjusted income from operations increased to $503 million, up over 80% year-over-year, demonstrating scalability.
- FDA approval of BEQALZI as the first and only BCL2 inhibitor in mantle cell lymphoma.
- Successful Phase III MANGROVE study for BRUKINSA, showing a chemo-free regimen was superior to standard of care with a hazard ratio of 0.57.
Qualified
- The CELESTIAL 301 study did not reach statistical superiority in the uMRD analysis versus the VO regimen, though the IDMC recommended continuation for the PFS endpoint.
- A tax audit settlement had an approximate $60 million impact on net income.
The full ledger
Open BeOne Medicines Ltd.’s full ledger
A free account opens 5 company ledgers a month. All 36 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 6, 2026
BeOne Medicines Q1 FY26 — Strong BRUKINSA Growth & Raised Full-Year Guidance
Read the full callDec 2025 (Q4 FY25) — Feb 26, 2026
BeOne Medicines Q4 FY25 — BRUKINSA Dominance and Pipeline Expansion
Read the full callEvery analysed call
BeOne Medicines AG earnings calls (ONC)
Financials
What the filings say
Net profit, year on year: +151% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,002 | 1,128 | 1,117 | 1,315 | 1,412 | 1,498 | 1,513 | 1,705 |
| Expenses | 951 | 1,047 | 941 | 1,063 | 1,053 | 1,171 | 1,096 | 1,205 |
| Operating profit | -120 | -79 | 11 | 88 | 163 | 185 | 250 | 325 |
| Operating margin | −12.0% | −7.0% | 1.0% | 6.7% | 11.6% | 12.3% | 16.5% | 19.1% |
| Interest | — | — | 7 | 8 | — | — | 33 | 40 |
| Profit before tax | -98 | -85 | 21 | 100 | 147 | 149 | 259 | 312 |
| Tax rate | −23.4% | −78.0% | 93.9% | 5.3% | 15.2% | 55.4% | 12.3% | 24.1% |
| Net profit | -121 | -152 | 1 | 94 | 125 | 67 | 227 | 237 |
| EPS ($ per share) | -0.09 | — | 0 | 0.07 | 0.09 | — | 0.16 | 0.16 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -1,007 | -1,956 | -3,553 | -5,077 | -7,080 | -7,962 | -8,607 | -8,320 |
| Total liabilities | 496 | 634 | 1,732 | 2,403 | 1,996 | 2,268 | 2,589 | 3,827 |
| Fixed assets | 157 | 242 | 358 | 588 | 846 | 1,324 | 1,578 | 1,642 |
| Investments | 1,069 | 365 | 3,269 | 2,242 | 665 | 3 | — | — |
| Total assets | 2,250 | 1,612 | 5,601 | 8,536 | 6,379 | 5,805 | 5,921 | 8,189 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -548 | -750 | -1,283 | -1,299 | -1,497 | -1,157 | -141 | 1,128 |
| Cash from investing | -638 | 554 | -3,168 | 641 | 1,077 | 60 | -548 | -276 |
| Cash from financing | 1,691 | 86 | 5,203 | 3,637 | -19 | 416 | 193 | 1,059 |
| Net cash flow | 501 | -120 | 769 | 2,993 | -508 | -689 | -547 | 1,971 |
| Capital expenditure | -70 | -90 | -118 | -263 | -325 | -562 | -493 | -186 |
| Free cash flow | -618 | -840 | -1,401 | -1,562 | -1,822 | -1,719 | -633 | 942 |
ONC revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| BRUKINSA | — | — | — | — | — | — | — | 73% | — |
| TEVIMBRA | — | — | — | — | — | — | — | 13% | — |
| XGEVA | — | — | — | — | — | — | — | 6% | — |
| Other | — | — | — | — | — | — | — | 2% | — |
| BLINCYTO | — | — | — | — | — | — | — | 2% | — |
| Other Revenue | — | — | — | — | — | — | — | 1% | — |
| Amgen Royalty Revenue | — | — | — | — | 1% | 1% | 1% | 1% | +108.4% |
| KYPROLIS | — | — | — | — | — | — | — | 1% | — |
| POBEVCY | — | — | — | — | — | — | — | 1% | — |
| Novartis Broad Markets Revenue | — | — | — | — | <1% | <1% | <1% | <1% | +49.3% |
| Collaboration Other | 1% | 1% | 3% | — | <1% | <1% | <1% | <1% | +72.0% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
ONC operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Employees | <12KAnd on behalf of everyone here, I really want to thank the broader oncology community, the patients and families who inspire our work, the clinicians who partner with us every day and our almost 12,000 employees all around the world who continue to raise the bar.Source: earnings call transcript | 12K+I really want to thank the patients and the families that we serve, our physicians and our partners and our more than 12,000 colleagues and their families who focus and urgency make our progress possible.Source: earnings call transcript | 12K+And we do want to just take a moment to thank the patients, their families that we're serving, the physicians, our partners and our more than 12,000 colleagues and their families who focus with urgency every day to make this progress possible.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q2 FY2026 · share of revenue
- US 54% ↑ 3 pt
- CN 30% ↓ 8 pt
- Europe 12% ↑ 2 pt
- All Other Countries Except China and United States Of America 4% ↑ 2 pt
As ONC cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
282 filings between Nov 7, 2025 and Oct 13, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$380.09M
204 sales by 12 insiders
72% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 27
- Award — granted as compensation
- 48
- Option exercise — converted options into shares
Also filed: 3 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| OYLER JOHN | — | $327.88M | Aug 12, 2026 |
| Wang Xiaodong | — | $35.57M | Oct 13, 2026 |
| Wu Xiaobin | — | $8.75M | Aug 25, 2026 |
| Lee Chan Henry | — | $4.63M | Sep 30, 2026 |
| Wang Lai | — | $1.17M | Jun 23, 2026 |
| Sanders Corazon (Corsee) D. | — | $961.2K | May 22, 2026 |
| Rosenberg Aaron | — | $524.4K | Aug 3, 2026 |
| BAKER BROS. ADVISORS LP | — | $262.0K | May 22, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 13, 2026 | Wang Xiaodong Director | Option exercise 10b5-1 plan | 31,027 | $1.14M |
| Oct 13, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 7,167 | $2.51M |
| Oct 13, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 6,558 | $2.31M |
| Oct 13, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 1,260 | $445.1K |
| Oct 13, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 10,361 | $3.63M |
| Oct 13, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 5,681 | $2.00M |
| Sep 30, 2026 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 plan | 1,115 | $418.1K |
| Sep 28, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 120 | $43.0K |
| Sep 28, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 738 | $271.0K |
| Sep 28, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 3,419 | $1.24M |
| Sep 28, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 2,241 | $809.1K |
| Sep 28, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 40 | $14.4K |
| Sep 28, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 4,239 | $1.54M |
| Sep 28, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 2,047 | $748.9K |
| Sep 28, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 3,499 | $1.27M |
| Sep 28, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 14,525 | $5.32M |
| Sep 28, 2026 | Wang Xiaodong Director | Option exercise 10b5-1 plan | 31,028 | $1.14M |
| Sep 28, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 160 | $57.1K |
| Sep 8, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 6,278 | $2.21M |
| Sep 8, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 1,517 | $527.0K |
| Sep 8, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 1,721 | $598.9K |
| Sep 8, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 1,181 | $407.9K |
| Sep 8, 2026 | Wang Xiaodong Director | Option exercise 10b5-1 plan | 31,027 | $1.14M |
| Sep 8, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 7,492 | $2.61M |
| Sep 8, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 10,688 | $3.73M |
| Sep 8, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 2,841 | $983.4K |
| Sep 8, 2026 | Wang Xiaodong Director | Sale 10b5-1 plan | 6,569 | $2.30M |
| Sep 1, 2026 | Ball Titus B. Principal Accounting Officer | Sale | 132 | $47.0K |
| Aug 25, 2026 | Wu Xiaobin President and COO | Sale 10b5-1 plan | 280 | $106.4K |
| Aug 12, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 14,102 | $5.06M |
| Aug 12, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 20,899 | $7.49M |
| Aug 12, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 15,396 | $5.51M |
| Aug 12, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 2,515 | $896.4K |
| Aug 12, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 1,980 | $702.3K |
| Aug 11, 2026 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 plan | 796 | $126.6K |
| Aug 11, 2026 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 plan | 1,058 | $225.7K |
| Aug 11, 2026 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 plan | 812 | $157.9K |
| Aug 11, 2026 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 plan | 2,666 | $959.8K |
| Aug 11, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 13,695 | $4.92M |
| Aug 11, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 4 | $1.5K |
| Aug 11, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 1,200 | $439.6K |
| Aug 11, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 3,176 | $1.16M |
| Aug 11, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 5,211 | $1.90M |
| Aug 11, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 13,403 | $4.87M |
| Aug 11, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 11,568 | $4.19M |
| Aug 11, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 14,569 | $5.27M |
| Aug 11, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 8,081 | $2.91M |
| Aug 10, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 2,813 | $989.6K |
| Aug 10, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 67 | $23.4K |
| Aug 10, 2026 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 plan | 3,680 | $1.33M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for BeOne Medicines Ltd.
Free account. Everything above stays public.
Write why you follow BeOne Medicines Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading